Targeting the dynamic HSP90 complex in cancer (original) (raw)

• Wandinger, S. K., Richter, K. & Buchner, J. The Hsp90 chaperone machinery. J. Biol. Chem. 283, 18473–18477 (2008).
  Article CAS PubMed Google Scholar
• Zhao, R. et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120, 715–727 (2005).
  Article CAS PubMed Google Scholar
• Pratt, W. B. & Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood) 228, 111–133 (2003).
  Article CAS Google Scholar
• Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nature Rev. Cancer 5, 761–772 (2005).
  Article CAS Google Scholar
• Dezwaan, D. C. & Freeman, B. C. HSP90: the Rosetta stone for cellular protein dynamics? Cell Cycle 7, 1006–1012 (2008).
  Article CAS PubMed Google Scholar
• Pratt, W. B., Morishima, Y. & Osawa, Y. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J. Biol. Chem. 283, 22885–22889 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• McClellan, A. J. et al. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131, 121–135 (2007).
  Article CAS PubMed Google Scholar
• Tsaytler, P. A., Krijgsveld, J., Goerdayal, S. S., Rudiger, S. & Egmond, M. R. Novel Hsp90 partners discovered using complementary proteomic approaches. Cell Stress Chaperones 14, 629–638 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Freeman, B. C. & Yamamoto, K. R. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296, 2232–2235 (2002).
  Article CAS PubMed Google Scholar
• Zhao, R. & Houry, W. A. Hsp90: a chaperone for protein folding and gene regulation. Biochem. Cell Biol. 83, 703–710 (2005).
  Article CAS PubMed Google Scholar
• Tariq, M., Nussbaumer, U., Chen, Y., Beisel, C. & Paro, R. Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression. Proc. Natl Acad. Sci. USA 106, 1157–1162 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Eccles, S. A. et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68, 2850–2860 (2008).
  Article CAS PubMed Google Scholar
• Chiosis, G. & Tao, H. Purine-scaffold Hsp90 inhibitors. IDrugs 9, 778–782 (2006).
  CAS PubMed Google Scholar
• Kim, Y. S. et al. Update on Hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem. 9, 1479–1492 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Workman, P., Burrows, F., Neckers, L. & Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N. Y. Acad. Sci. 1113, 202–216 (2007).
  Article CAS PubMed Google Scholar
• Pearl, L. H. & Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75, 271–294 (2006).
  Article CAS PubMed Google Scholar
• Donnelly, A. & Blagg, B. S. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 15, 2702–2717 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Ali, M. M. et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 440, 1013–1017 (2006). This paper describes the first crystal structure of a full-length HSP90–co-chaperone complex.
  Article CAS PubMed PubMed Central Google Scholar
• Prodromou, C. & Pearl, L. H. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets 3, 301–323 (2003).
  Article CAS PubMed Google Scholar
• Wayne, N. & Bolon, D. N. Dimerization of Hsp90 is required for in vivo function. Design and analysis of monomers and dimers. J. Biol. Chem. 282, 35386–35395 (2007).
  Article CAS PubMed Google Scholar
• Onuoha, S. C., Coulstock, E. T., Grossmann, J. G. & Jackson, S. E. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J. Mol. Biol. 379, 732–744 (2008).
  Article CAS PubMed Google Scholar
• Vaughan, C. K. et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 23, 697–707 (2006). This paper describes the first structure of an HSP90–co-chaperone–client protein complex.
  Article CAS PubMed PubMed Central Google Scholar
• Southworth, D. R. & Agard, D. A. Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle. Mol. Cell 32, 631–640 (2008). This paper reports the species-dependence of the conformational states sampled by HSP90.
  Article CAS PubMed PubMed Central Google Scholar
• McLaughlin, S. H., Ventouras, L. A., Lobbezoo, B. & Jackson, S. E. Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform. J. Mol. Biol. 344, 813–826 (2004).
  Article CAS PubMed Google Scholar
• Meyer, P. et al. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J. 23, 1402–1410 (2004).
  Article CAS PubMed Google Scholar
• Mickler, M., Hessling, M., Ratzke, C., Buchner, J. & Hugel, T. The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis. Nature Struct. Mol. Biol. 16, 281–286 (2009).
  Article CAS Google Scholar
• Hessling, M., Richter, K. & Buchner, J. Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nature Struct. Mol. Biol. 16, 287–293 (2009). References 26 and 27 dissect the conformational intermediates of the HSP90 chaperone cycle.
  Article CAS Google Scholar
• Panaretou, B. et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol. Cell 10, 1307–1318 (2002).
  Article CAS PubMed Google Scholar
• Forafonov, F. et al. p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity. Mol. Cell. Biol. 28, 3446–3456 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Retzlaff, M. et al. Asymmetric activation of the hsp90 dimer by its cochaperone aha1. Mol. Cell 37, 344–354 (2010).
  Article CAS PubMed Google Scholar
• Koulov, A. V. et al. Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis. Mol. Biol. Cell 21, 871–884 (2010). This paper describes how AHA1 interaction with HSP90 affects client interaction with the HSP90 complex and chaperone efficiency.
  Article CAS PubMed PubMed Central Google Scholar
• Miyata, Y. & Nishida, E. Evaluating CK2 activity with the antibody specific for the CK2-phosphorylated form of a kinase-targeting cochaperone Cdc37. Mol. Cell. Biochem. 316, 127–134 (2008).
  Article CAS PubMed Google Scholar
• Smith, J. R. & Workman, P. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Cell Cycle 8, 362–372 (2009).
  Article CAS PubMed Google Scholar
• Echeverria, P. C. et al. Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin β. Mol. Cell. Biol. 29, 4788–4797 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Pratt, W. B., Morishima, Y., Murphy, M. & Harrell, M. Chaperoning of glucocorticoid receptors. Handb. Exp. Pharmacol. 172, 111–138 (2006).
  Article CAS Google Scholar
• Wochnik, G. M. et al. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J. Biol. Chem. 280, 4609–4616 (2005).
  Article CAS PubMed Google Scholar
• Zhang, M. et al. Structural and functional coupling of Hsp90- and Sgt1-centred multi-protein complexes. EMBO J. 27, 2789–2798 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Boulon, S. et al. The Hsp90 chaperone controls the biogenesis of L7Ae RNPs through conserved machinery. J. Cell Biol. 180, 579–595 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Vaughan, C. K. et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol. Cell 31, 886–895 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• McDowell, C. L., Bryan Sutton, R. & Obermann, W. M. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue. Int. J. Biol. Macromol. 45, 310–314 (2009).
  Article CAS PubMed Google Scholar
• Gray, P. J. Jr, Stevenson, M. A. & Calderwood, S. K. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res. 67, 11942–11950 (2007).
  Article CAS PubMed Google Scholar
• Holmes, J. L., Sharp, S. Y., Hobbs, S. & Workman, P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 68, 1188–1197 (2008).
  Article PubMed CAS Google Scholar
• Scroggins, B. T. & Neckers, L. Post-translational modification of heat shock protein 90: impact on chaperone function. Expert Opin. Drug Discov. 2, 1403–1414 (2007).
  Article CAS PubMed Google Scholar
• Mimnaugh, E. G., Worland, P. J., Whitesell, L. & Neckers, L. M. Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase. J. Biol. Chem. 270, 28654–28659 (1995).
  Article CAS PubMed Google Scholar
• Wandinger, S. K., Suhre, M. H., Wegele, H. & Buchner, J. The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J. 25, 367–376 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Duval, M., Le Boeuf, F., Huot, J. & Gratton, J. P. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol. Biol. Cell 18, 4659–4668 (2007). This paper reports the tyrosine phosphorylation of HSP90 by a client kinase.
  Article CAS PubMed PubMed Central Google Scholar
• Kurokawa, M., Zhao, C., Reya, T. & Kornbluth, S. Inhibition of apoptosome formation by suppression of Hsp90β phosphorylation in tyrosine kinase-induced leukemias. Mol. Cell. Biol. 28, 5494–5506 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Old, W. M. et al. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol. Cell 34, 115–131 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Lees-Miller, S. P. & Anderson, C. W. Two human 90-kDa heat shock proteins are phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein kinase II. J. Biol. Chem. 264, 2431–2437 (1989).
  CAS PubMed Google Scholar
• Miyata, Y. Protein kinase CK2 in health and disease: CK2: the kinase controlling the Hsp90 chaperone machinery. Cell. Mol. Life Sci. 66, 1840–1849 (2009).
  Article CAS PubMed Google Scholar
• Harvey, S. L., Charlet, A., Haas, W., Gygi, S. P. & Kellogg, D. R. Cdk1-dependent regulation of the mitotic inhibitor Wee1. Cell 122, 407–420 (2005).
  Article CAS PubMed Google Scholar
• Mollapour, M. et al. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol. Cell 37, 333–343 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Mollapour, M., Tsutsumi, S. & Neckers, L. Hsp90 phosphorylation, Wee1 and the cell cycle. Cell Cycle 9, 1–7 (2010).
  Article Google Scholar
• Yu, X. et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94, 504–513 (2002).
  Article CAS PubMed Google Scholar
• Kovacs, J. J. et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18, 601–607 (2005).
  Article CAS PubMed Google Scholar
• Scroggins, B. T. et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 25, 151–159 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, Y. et al. Role of acetylation and extracellular location of heat shock protein 90α in tumor cell invasion. Cancer Res. 68, 4833–4842 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Maloney, A. et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 67, 3239–3253 (2007).
  Article CAS PubMed Google Scholar
• Martinez-Ruiz, A. et al. _S_-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc. Natl Acad. Sci. USA 102, 8525–8530 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Morra, G., Verkhivker, G. & Colombo, G. Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer. PLoS Comput. Biol. 5, e1000323 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Retzlaff, M. et al. Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep. 10, 1147–1153 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Compton, S. A., Elmore, L. W., Haydu, K., Jackson-Cook, C. K. & Holt, S. E. Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells. Mol. Cell. Biol. 26, 1452–1462 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Toogun, O. A., Dezwaan, D. C. & Freeman, B. C. The hsp90 molecular chaperone modulates multiple telomerase activities. Mol. Cell. Biol. 28, 457–467 (2008).
  Article CAS PubMed Google Scholar
• Csermely, P., Schnaider, T., Soti, C., Prohaszka, Z. & Nardai, G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. 79, 129–168 (1998).
  Article CAS PubMed Google Scholar
• Conzen, S. D. Minireview: nuclear receptors and breast cancer. Mol. Endocrinol. 22, 2215–2228 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Echeverria, P. C. & Picard, D. Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochim. Biophys. Acta 1803, 641–649 (2009).
  Article PubMed CAS Google Scholar
• Zou, J., Guo, Y., Guettouche, T., Smith, D. F. & Voellmy, R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94, 471–480 (1998).
  Article CAS PubMed Google Scholar
• Conde, R., Belak, Z. R., Nair, M., O'Carroll, R. F. & Ovsenek, N. Modulation of Hsf1 activity by novobiocin and geldanamycin. Biochem. Cell Biol. 87, 845–851 (2009).
  Article CAS PubMed Google Scholar
• Dai, C., Whitesell, L., Rogers, A. B. & Lindquist, S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130, 1005–1018 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Min, J. N., Huang, L., Zimonjic, D. B., Moskophidis, D. & Mivechi, N. F. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 26, 5086–5097 (2007). References 69 and 70 highlight the importance of HSF1 for carcinogenesis.
  Article CAS PubMed Google Scholar
• Au, Q., Zhang, Y., Barber, J. R., Ng, S. C. & Zhang, B. Identification of inhibitors of HSF1 functional activity by high-content target-based screening. J. Biomol. Screen. 14, 1165–1175 (2009).
  Article CAS PubMed Google Scholar
• Ci, W. et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 113, 5536–5548 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Cerchietti, L. C. et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 113, 3397–3405 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Cerchietti, L. C. et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature Med. 15, 1369–1376 (2009).
  Article CAS PubMed Google Scholar
• Choo, A. et al. The role of IRF1 and IRF2 transcription factors in leukaemogenesis. Curr. Gene Ther. 6, 543–550 (2006).
  Article CAS PubMed Google Scholar
• Narayan, V., Eckert, M., Zylicz, A., Zylicz, M. & Ball, K. L. Cooperative regulation of the interferon regulatory factor-1 tumor suppressor protein by core components of the molecular chaperone machinery. J. Biol. Chem. 284, 25889–25899 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Bach, C. & Slany, R. K. Molecular pathology of mixed-lineage leukemia. Future Oncol. 5, 1271–1281 (2009).
  Article CAS PubMed Google Scholar
• Pal, S., Vishwanath, S. N., Erdjument-Bromage, H., Tempst, P. & Sif, S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol. Cell. Biol. 24, 9630–9645 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Hamamoto, R. et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nature Cell Biol. 6, 731–740 (2004). This paper reports that HSP90 inhibitor treatment suppresses SMYD3 activity in cancer cells.
  Article CAS PubMed Google Scholar
• Komatsu, S. et al. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 30, 1139–1146 (2009).
  Article CAS PubMed Google Scholar
• Abu-Farha, M. et al. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol. Cell. Proteomics 7, 560–572 (2008).
  Article CAS PubMed Google Scholar
• Sekimoto, T. et al. The molecular chaperone Hsp90 regulates accumulation of DNA polymerase η at replication stalling sites in UV-irradiated cells. Mol. Cell 37, 79–89 (2010).
  Article CAS PubMed Google Scholar
• Specchia, V. et al. Hsp90 prevents phenotypic variation by suppressing the mutagenic activity of transposons. Nature 463, 662–665 (2010).
  Article CAS PubMed Google Scholar
• Brennecke, J. et al. Discrete small RNA-generating loci as master regulators of transposon activity in Drosophila. Cell 128, 1089–1103 (2007).
  Article CAS PubMed Google Scholar
• Nishida, K. M. et al. Functional involvement of Tudor and dPRMT5 in the piRNA processing pathway in Drosophila germlines. EMBO J. 28, 3820–3831 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Oh, W. K. et al. A single arm phase II trial of IPI-504 in patients with castration resistant prostate cancer (CRPC). Genitourinary Cancers Symp. Abstr. 219 (2009).
• Heath, E. I. et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14, 7940–7946 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Yano, A. et al. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc. Natl Acad. Sci. USA 105, 15541–15546 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Zoubeidi, A. et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 67, 10455–10465 (2007).
  Article CAS PubMed Google Scholar
• Solit, D. B. et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 14, 8302–8307 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Grbovic, O. M. et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl Acad. Sci. USA 103, 657–662 (2006).
  Article CAS Google Scholar
• da Rocha Dias, S. et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65, 10686–10691 (2005).
  Article CAS PubMed Google Scholar
• Mimnaugh, E. G., Chavany, C. & Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271, 22796–22801 (1996).
  Article CAS PubMed Google Scholar
• Modi, S. et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J. Clin. Oncol. Abstr. 26, 1027 (2008).
  Article Google Scholar
• Xu, W. et al. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. Br. J. Cancer 97, 741–744 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Chandarlapaty, S. et al. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29, 325–334 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Caldas-Lopes, E. et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl Acad. Sci. USA 106, 8368–8373 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Richardson, P. G. et al. Tanespimycin + bortezomib demonstrates safety, activity, and effective target inhibition in relapsed/refractory myeloma patients: updated results of a phase 1/2 study. 51st Am. Soc. Hematogy Annu. Meet. Abstr. (2009).
• Mimnaugh, E. G., Xu, W., Vos, M., Yuan, X. & Neckers, L. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol. Cancer Res. 4, 667–681 (2006).
  Article CAS PubMed Google Scholar
• Mitsiades, C. S. et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 107, 1092–1100 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Frebel, K. & Wiese, S. Signalling molecules essential for neuronal survival and differentiation. Biochem. Soc. Trans. 34, 1287–1290 (2006).
  Article CAS PubMed Google Scholar
• Fionda, C. et al. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J. Immunol. 183, 4385–4394 (2009). This paper shows that HSP90 inhibitors enhance NK-dependent recognition and lysis of myleoma cells in an HSF1-dependent manner.
  Article CAS PubMed Google Scholar
• Tse, A. N., Sheikh, T. N., Alan, H., Chou, T. C. & Schwartz, G. K. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol. Pharmacol. 75, 124–133 (2009).
  Article CAS PubMed Google Scholar
• Arlander, S. J. et al. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J. Biol. Chem. 281, 2989–2998 (2006).
  Article CAS PubMed Google Scholar
• Tse, A. N. et al. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin. Cancer Res. 14, 6704–6711 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hubbard, J. et al. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest. New Drugs 15 Jan 2010 [epub ahead of print].
• Hwang, M., Moretti, L. & Lu, B. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr. Med. Chem. 16, 3081–3092 (2009).
  Article CAS PubMed Google Scholar
• Reikvam, H., Ersvaer, E. & Bruserud, O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr. Cancer Drug Targets 9, 761–776 (2009).
  Article CAS PubMed Google Scholar
• Lancet, J. E. et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022,17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24, 699–705 (2010).
  Article CAS PubMed Google Scholar
• Weisberg, E. et al. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist. Updat. 12, 81–89 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Shiotsu, Y. et al. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96, 2284–2291 (2000).
  CAS PubMed Google Scholar
• Peng, C., Li, D. & Li, S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 6, 2227–2231 (2007).
  Article CAS PubMed Google Scholar
• O'Hare, T., Eide, C. A. & Deininger, M. W. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin. Investig. Drugs 17, 865–878 (2008).
  Article CAS PubMed Google Scholar
• Peng, C. et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110, 678–685 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Castro, J. E. et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 106, 2506–2512 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Elfiky, A. et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience. J. Clin. Oncol. Abstr. 26, 2503 (2008).
  Article Google Scholar
• Gallegos Ruiz, M. I. et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS ONE 3, e0001722 (2008).
  Article PubMed CAS Google Scholar
• Sequist, L. V. et al. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. J. Clin. Oncol. Abstr. 27, 8073 (2009).
  Google Scholar
• Shimamura, T. & Shapiro, G. I. Heat shock protein 90 inhibition in lung cancer. J. Thorac. Oncol. 3, S152–S159 (2008).
  Article PubMed PubMed Central Google Scholar
• Shimamura, T. et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 68, 5827–5838 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Banerji, U. et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 23, 4152–4161 (2005).
  Article CAS PubMed Google Scholar
• Grem, J. L. et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol. 23, 1885–1893 (2005).
  Article CAS PubMed Google Scholar
• Ramanathan, R. K. et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J. Clin. Oncol. 28, 1520–1526 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Eiseman, J. L. et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 55, 21–32 (2005).
  Article CAS PubMed Google Scholar
• Vilenchik, M. et al. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 11, 787–797 (2004).
  Article CAS PubMed Google Scholar
• Kamal, A. et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407–410 (2003).
  Article CAS PubMed Google Scholar
• Kummar, S. et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur. J. Cancer 46, 340–347 (2010).
  Article CAS PubMed Google Scholar
• Dakappagari, N. et al. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 15, 31–38 (2009).
  Article CAS Google Scholar
• Demetri, G. D. et al. Inhibition of the heat shock protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: updated results of a phase I trial. J. Clin. Oncol. Abstr. 25, 10024 (2007).
  Google Scholar
• Smith-Jones, P. M., Solit, D., Afroze, F., Rosen, N. & Larson, S. M. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J. Nucl. Med. 47, 793–796 (2006). This paper describes a new non-invasive imaging approach to monitor anti-tumour HSP90 inhibitor activity in vivo.
  CAS PubMed Google Scholar
• Oude Munnink, T. H. et al. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur. J. Cancer 46, 678–684 (2009).
  Article PubMed CAS Google Scholar
• Kramer-Marek, G., Kiesewetter, D. O. & Capala, J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18F-labeled affibody molecules. J. Nucl. Med. 50, 1131–1139 (2009).
  Article CAS PubMed Google Scholar
• Holland, J. P. et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS ONE 5, e8859 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Le, H. C. et al. Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magn. Reson. Med. 62, 1112–1119 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Chung, Y. L. et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl Cancer Inst. 95, 1624–1633 (2003).
  Article CAS PubMed Google Scholar
• Liu, D. et al. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br. J. Cancer 87, 783–789 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G. & Workman, P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl Cancer Inst. 91, 1940–1949 (1999).
  Article CAS PubMed Google Scholar
• Guo, W. et al. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 65, 10006–10015 (2005).
  Article CAS PubMed Google Scholar
• Gaspar, N. et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res. 69, 1966–1975 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Erlichman, C. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin. Investig. Drugs 18, 861–868 (2009).
  Article CAS PubMed Google Scholar
• McCollum, A. K., Teneyck, C. J., Sauer, B. M., Toft, D. O. & Erlichman, C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res. 66, 10967–10975 (2006).
  Article CAS PubMed Google Scholar
• Powers, M. V., Clarke, P. A. & Workman, P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14, 250–262 (2008).
  Article CAS PubMed Google Scholar
• Evans, C. G., Chang, L. & Gestwicki, J. E. Heat shock protein 70 (Hsp70) as an emerging drug target. J. Med. Chem. 24 Mar 2010 (doi:10.1021/jm100054f).
• Powers, M. V. et al. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 9, 1542–1550 (2010).
  Article CAS PubMed Google Scholar
• Hadchity, E. et al. Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma. Mol. Ther. 17, 1387–1394 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Roe, S. M. et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42, 260–266 (1999).
  Article CAS PubMed Google Scholar
• Prodromou, C. et al. Structural basis of the radicicol resistance displayed by a fungal hsp90. ACS Chem. Biol. 4, 289–297 (2009).
  Article CAS PubMed Google Scholar
• Matthews, S. B. et al. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate 70, 27–36 (2010).
  Article CAS PubMed Google Scholar
• Shelton, S. N. et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol. Pharmacol. 76, 1314–1322 (2009). References 148 and 149 describe new C-terminal HSP90 inhibitors with potent anticancer activity.
  Article CAS PubMed PubMed Central Google Scholar
• Radanyi, C. et al. Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells. Cancer Lett. 274, 88–94 (2009).
  Article CAS PubMed Google Scholar
• Zhang, T. et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7, 162–170 (2008).
  Article CAS PubMed Google Scholar
• Sreeramulu, S., Gande, S. L., Gobel, M. & Schwalbe, H. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew. Chem. Int. Ed. Engl. 48, 5853–5855 (2009).
  Article CAS PubMed Google Scholar
• Chakraborty, A. et al. HSP90 regulates cell survival via inositol hexakisphosphate kinase-2. Proc. Natl Acad. Sci. USA 105, 1134–1139 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Voss, A. K., Thomas, T. & Gruss, P. Mice lacking HSP90β fail to develop a placental labyrinth. Development 127, 1–11 (2000).
  CAS PubMed Google Scholar
• Dollins, D. E., Warren, J. J., Immormino, R. M. & Gewirth, D. T. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol. Cell 28, 41–56 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Frey, S., Leskovar, A., Reinstein, J. & Buchner, J. The ATPase cycle of the endoplasmic chaperone Grp94. J. Biol. Chem. 282, 35612–35620 (2007).
  Article CAS PubMed Google Scholar
• Leskovar, A., Wegele, H., Werbeck, N. D., Buchner, J. & Reinstein, J. The ATPase cycle of the mitochondrial Hsp90 analog Trap1. J. Biol. Chem. 283, 11677–11688 (2008).
  Article CAS PubMed Google Scholar
• Immormino, R. M. et al. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. J. Mol. Biol. 388, 1033–1042 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Felts, S. J. et al. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J. Biol. Chem. 275, 3305–3312 (2000).
  Article CAS PubMed Google Scholar
• Hua, G., Zhang, Q. & Fan, Z. Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J. Biol. Chem. 282, 20553–20560 (2007).
  Article CAS PubMed Google Scholar
• Kang, B. H. et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 119, 454–464 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Leav, I. et al. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am. J. Pathol. 176, 393–401 (2009).
  Article PubMed CAS Google Scholar
• Pridgeon, J. W., Olzmann, J. A., Chin, L. S. & Li, L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 5, e172 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Sidera, K. & Patsavoudi, E. Extracellular HSP90: conquering the cell surface. Cell Cycle 7, 1564–1568 (2008).
  Article CAS PubMed Google Scholar
• Eustace, B. K. et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nature Cell Biol. 6, 507–514 (2004). This paper describes an important role for secreted HSP90 in cancer cell motility and invasion.
  Article CAS PubMed Google Scholar
• Becker, B. et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp. Dermatol. 13, 27–32 (2004).
  Article CAS PubMed Google Scholar
• Tsutsumi, S. et al. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 27, 2478–2487 (2008).
  Article CAS PubMed Google Scholar
• Cheng, C. F. et al. Transforming growth factor alpha (TGFα)-stimulated secretion of HSP90alpha: using the receptor LRP-1/CD91 to promote human skin cell migration against a TGFβ-rich environment during wound healing. Mol. Cell. Biol. 28, 3344–3358 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Li, W. et al. Extracellular heat shock protein-90α: linking hypoxia to skin cell motility and wound healing. EMBO J. 26, 1221–1233 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Tsutsumi, S. et al. Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nature Struct. Mol. Biol. 16, 1141–1147 (2009).
  Article CAS Google Scholar
• Sidera, K., Gaitanou, M., Stellas, D., Matsas, R. & Patsavoudi, E. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J. Biol. Chem. 283, 2031–2041 (2008).
  Article CAS PubMed Google Scholar
• Annamalai, B., Liu, X., Gopal, U. & Isaacs, J. S. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis. Mol. Cancer Res. 7, 1021–1032 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kawabe, M. et al. Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. Cancer Res. 69, 6995–7003 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Wesa, A. K. et al. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. J. Immunol. 181, 7721–7727 (2008).
  Article CAS PubMed Google Scholar
• Stuehler, C. et al. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. Blood 114, 2829–2836 (2009).
  Article CAS PubMed Google Scholar